Insilico Medicine vs LSEG Workspace AI

Enterprise and institutional licensing for pharmaceutical partners. No public access. Public company listed on NASDAQ.

Enterprise subscription through LSEG Data & Analytics. No public pricing. Formerly known as Refinitiv Eikon.

Drug discovery research data processed under enterprise partnership data handling agreements. Review applicable regulatory requirements for clinical programme data.

Financial data processed under LSEG enterprise data handling agreements. Customer data not used for model training per LSEG enterprise terms.

• ✓INS018_055 in Phase 2 clinical trials is the most advanced AI-designed drug in human trials
• ✓Chemistry42 generative AI designs novel molecules rather than only screening existing libraries
• ✓First company to advance a fully AI-designed drug candidate to clinical trials
• ✓NASDAQ listing (ILAB) provides financial transparency for pharma partnership assessment

• ✓AI on LSEG's Reuters newswire and Refinitiv financial database provides intelligence on one of the largest financial data sources
• ✓Natural language search reduces friction in accessing complex financial data for professionals
• ✓For LSEG Workspace subscribers, AI capabilities require no new platform adoption
• ✓Earnings insights AI scales transcript analysis coverage without proportional analyst headcount

• ✕Drug discovery is inherently long-cycle — AI acceleration is still measured in years, not weeks
• ✕Clinical success probability remains uncertain — most drug candidates fail in clinical trials
• ✕Enterprise partnership model means capabilities are not broadly accessible as a self-serve platform

• ✕Enterprise-only through existing LSEG subscriptions at significant cost
• ✕Platform rebranding from Refinitiv to LSEG has caused some continuity and naming confusion
• ✕Bloomberg Terminal's AI features are more mature and better established among institutional investors